Reported about 12 hours ago
WeightWatchers' stock rose sharply after its plan to sell cheap compounded versions of popular weight-loss drugs Ozempic and Wegovy was made public. However, analysts caution that this strategy may not be sustainable in the long run, highlighting that removing these drugs from the FDA's shortage list could severely impact WeightWatchers' ability to compete. The company's attempts to pivot from dieting programs to the weight-loss drug market might undermine its core business, potentially leading to significant challenges ahead.
Source: YAHOO